Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.

Bang-Bin ChenPo-Chin LiangTiffany Ting-Fang ShihTsung-Hao LiuYing-Chun ShenLi-Chun LuZhong-Zhe LinChiun HsuChih-Hung HsuAnn-Lii ChengYu-Yun Shao

Published in: European radiology (2022)

• Sarcopenia and myosteatosis can be evaluated by CT at L3 level. • Sarcopenia, myosteatosis, and sarcopenic obesity were associated with poor survival outcomes in patients who underwent immunotherapy for advanced HCC. • Myosteatosis was an independent predictor of PFS and OS, and sarcopenia was independent for OS in these patients.

Keyphrases

end stage renal disease
skeletal muscle
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
type diabetes
metabolic syndrome
magnetic resonance imaging
adipose tissue
patient reported